Shionogi misses primary endpoint in Phase 3 for Covid-19 antiviral
Shionogi’s once-daily Covid-19 antiviral ensitrelvir missed the primary endpoint in a Phase 3 study, two months after scoring full approval in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
